share_log

Monte Rosa Therapeutics Analyst Ratings

Monte Rosa Therapeutics Analyst Ratings

蒙特罗萨治疗分析师评级
Benzinga Analyst Ratings ·  2023/01/03 04:37
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/03/2023 149.67% Wells Fargo → $19 Upgrades Equal-Weight → Overweight
10/13/2022 189.09% UBS → $22 Initiates Coverage On → Buy
08/15/2022 162.81% Jefferies → $20 Initiates Coverage On → Buy
05/12/2022 175.95% Piper Sandler $40 → $21 Maintains Overweight
04/28/2022 149.67% Credit Suisse → $19 Initiates Coverage On → Neutral
02/10/2022 149.67% Wells Fargo → $19 Initiates Coverage On → Equal-Weight
10/14/2021 162.81% SVB Leerink → $20 Initiates Coverage On → Market Perform
07/19/2021 294.22% Guggenheim → $30 Initiates Coverage On → Buy
07/19/2021 425.62% Piper Sandler → $40 Initiates Coverage On → Overweight
07/19/2021 399.34% JP Morgan → $38 Initiates Coverage On → Overweight
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
01/03/2023 149.67% 富国银行 →$19 升级 等重→超重
10/13/2022 189.09% 瑞银集团 →$22 开始承保 →购买
2022年08月15日 162.81% 杰富瑞 →$20 开始承保 →购买
2022年05月12日 175.95% 派珀·桑德勒 $40→$21 维护 超重
04/28/2022 149.67% 瑞士信贷 →$19 开始承保 →中性
02/10/2022 149.67% 富国银行 →$19 开始承保 →等重
10/14/2021 162.81% SVB Leerink →$20 开始承保 →市场表现
07/19/2021 294.22% 古根海姆 →$30 开始承保 →购买
07/19/2021 425.62% 派珀·桑德勒 →$40 开始承保 →超重
07/19/2021 399.34% 摩根大通 →$38 开始承保 →超重

What is the target price for Monte Rosa Therapeutics (GLUE)?

蒙特罗萨治疗公司(GLUE)的目标价格是多少？

The latest price target for Monte Rosa Therapeutics (NASDAQ: GLUE) was reported by Wells Fargo on January 3, 2023. The analyst firm set a price target for $19.00 expecting GLUE to rise to within 12 months (a possible 149.67% upside). 6 analyst firms have reported ratings in the last year.

富国银行于2023年1月3日报道了蒙特罗萨治疗公司(纳斯达克：GLUE)的最新目标价。这家分析公司将目标价定为19美元，预计12个月内胶价将上涨至149.67%。6家分析公司在过去一年公布了评级。

What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?

蒙特罗萨治疗公司(GLUE)的最新分析师评级是多少？

The latest analyst rating for Monte Rosa Therapeutics (NASDAQ: GLUE) was provided by Wells Fargo, and Monte Rosa Therapeutics upgraded their overweight rating.

蒙特罗萨治疗公司(纳斯达克代码：GLUE)的最新分析师评级由富国银行提供，蒙特罗萨治疗公司上调了其增持评级。

When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?

蒙特罗萨治疗公司(GLUE)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on January 3, 2023 so you should expect the next rating to be made available sometime around January 3, 2024.

分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与蒙特罗萨治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。蒙特罗萨治疗公司的上一次评级是在2023年1月3日提交的，所以你应该预计下一次评级将在2024年1月3日左右的某个时候提供。

Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?

分析师对蒙特罗萨治疗公司(GLUE)的评级正确吗？

While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a upgraded with a price target of $0.00 to $19.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $7.61, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的蒙特罗萨治疗公司(GLUE)评级被上调，目标价为0.00美元至19.00美元。蒙特罗萨治疗公司(GLUE)目前的交易价格为7.61美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发